Better Outcomes in Living donor liver transplantation with Terlipressin

Double-blind Randomized controlled trial of the peri-operative use of terlipressin in adult living donor liver transplantation. - BOLT (Better Outcomes with Terlipressin in Living donor liver transplantation)

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/10/004072

Enrollment

Registered

2013-10-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Adult End stage liver disease patients undergoing living donor liver transplantation

Interventions

Intervention1: Terlipressin: Terlipressin infusion started during living donor liver transplantation and continued for 72 hours postoperatively. Initial bolus of 1mg over 30 minutes followed by 2micro

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients undergoing first living donor liver transplantation for primary liver disease GRWR

Exclusion criteria

Exclusion criteria: Combined liver-kidney transplants Significant pre-operative renal dysfunction (eGFR Significant uncorrected coronary artery disease Urgent transplants Re-transplants

Design outcomes

Primary

Measure	Time frame
Portal pressureTimepoint: Before recipient hepatectomy After arterial reperfusion	—

Secondary

Measure	Time frame
Blood loss Blood product requirement Intraoperative urine output Intraoperative lactate Intraoperative inotropic requirement Postoperative renal dysfunction Postoperative complications ICU stay Hospital stay Adverse effects of trial medicationTimepoint: Intraoperative Postoperative	—

Countries

India

Contacts

Public ContactMettu Srinivas Reddy

Global Hospital and Health City

smettu.reddy@gmail.com9840054648

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026